ModerateAngiotensin II receptor blocker (ARB, sartan)×Antiepileptics. Fatty acid derivatives
Updated · Methodology
Mechanism
Valproic acid is strongly bound to plasma proteins, and according to its SmPC other highly protein-bound drugs, such as acetylsalicylic acid, may raise the blood level of free, unbound valproic acid (Depakine Crono SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Olmesartan is 99.7% bound to plasma proteins. Its SmPC, however, states that clinically relevant protein-binding displacement interactions with other highly bound drugs are unlikely, as confirmed by the lack of a clinically significant interaction with warfarin (Olmetec SmPC, AEMPS). Olmesartan forms no other significant metabolites, does not inhibit cytochrome P450 enzymes and is eliminated about 40% in urine and 60% in bile (Olmetec SmPC, AEMPS, and Benicar label, US Food and Drug Administration, FDA). The main metabolic pathway of valproic acid is UGT glucuronidation, about 40% of the dose. Olmesartan is not among the drugs that, according to the valproic acid SmPC, change valproic acid levels (Depakine Crono SmPC, AEMPS).
Symptoms
The documents describe no symptoms linked to this combination. The main risks of valproic acid are serious liver injury, pancreatitis and raised blood ammonia with ataxia, impaired consciousness and vomiting, and it very commonly causes tremor and nausea (Depakine Crono SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Olmesartan commonly causes dizziness and headache and can lower blood pressure, especially after the first dose in people with volume depletion. It rarely raises blood potassium and very rarely causes severe chronic diarrhoea with weight loss (Olmetec SmPC, AEMPS).
Management
No document names the pair, but by its own documents olmesartan is highly bound to plasma proteins. It therefore belongs to the group of drugs that, according to the valproic acid SmPC, may raise free valproic acid levels (Depakine Crono SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Olmetec SmPC, AEMPS, and Benicar label, US Food and Drug Administration, FDA). The documents disagree here: the valproic acid SmPC gives no instruction for this group, while the olmesartan SmPC states that clinically relevant protein-binding displacement interactions are unlikely (Depakine Crono and Olmetec SmPCs, AEMPS). Doses are not changed in advance. Total serum valproate poorly reflects its active free fraction, and the free fraction is higher than expected in older people and in liver and kidney disease (Depakote label, FDA). In renal impairment, the valproic acid dose may need to be reduced and is adjusted by clinical response, because plasma levels can be misleading (Depakine Crono SmPC, AEMPS). In people with renal impairment taking olmesartan, serum potassium and creatinine are checked periodically, and olmesartan is not recommended when creatinine clearance is below 20 mL/min (Olmetec SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Depakote (divalproex sodium) delayed-release tablets prescribing information (2026)– FDA, DailyMed, Depakote, AbbVie Inc., setid 08a65cf4-7749-4ceb-6895-8f4805e2b01f, revisión 03/2026, sección 5.15
- AEMPS: Ficha técnica: Ácido valproico, Depakine Crono 500 mg (nº registro 60350) (2026)– AEMPS, CIMA, nº registro 60350 (Depakine Crono 500 mg comprimidos de liberación prolongada, Sanofi), revisión 09/2026, secciones 4.1, 4.2, 4.4, 4.5 y 4.6
- AEMPS: Ficha técnica: Olmesartán medoxomilo, Olmetec 20 mg (nº registro 65496), sección 4.5 (2025)– AEMPS, CIMA, nº registro 65496 (Olmetec 20 mg comprimidos recubiertos, Daiichi Sankyo España), revisión 06/2025, secciones 4.4, 4.5 y 5.2
- FDA: Benicar (olmesartan medoxomil) prescribing information (2025)– FDA, DailyMed setid dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (Cosette Pharmaceuticals, NDA 021286), revised 09/2025 (version 1), sections 7 and 12.3